RS62463B1 - Postupci za unapređivanje odgovora t ćelija - Google Patents
Postupci za unapređivanje odgovora t ćelijaInfo
- Publication number
- RS62463B1 RS62463B1 RS20211221A RSP20211221A RS62463B1 RS 62463 B1 RS62463 B1 RS 62463B1 RS 20211221 A RS20211221 A RS 20211221A RS P20211221 A RSP20211221 A RS P20211221A RS 62463 B1 RS62463 B1 RS 62463B1
- Authority
- RS
- Serbia
- Prior art keywords
- promoting
- methods
- cells response
- cells
- response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1732—Lectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306381 | 2016-10-21 | ||
| EP17305988 | 2017-07-24 | ||
| PCT/EP2017/076911 WO2018073440A1 (en) | 2016-10-21 | 2017-10-20 | Methods for promoting t cells response |
| EP17797066.2A EP3529262B1 (en) | 2016-10-21 | 2017-10-20 | Methods for promoting t cells response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62463B1 true RS62463B1 (sr) | 2021-11-30 |
Family
ID=60293924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20211221A RS62463B1 (sr) | 2016-10-21 | 2017-10-20 | Postupci za unapređivanje odgovora t ćelija |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11365257B2 (sr) |
| EP (2) | EP3950709B1 (sr) |
| JP (2) | JP7032396B6 (sr) |
| KR (1) | KR102646708B1 (sr) |
| CN (1) | CN110291102A (sr) |
| AU (1) | AU2017345286B2 (sr) |
| CA (1) | CA3039348C (sr) |
| CY (1) | CY1124584T1 (sr) |
| DK (1) | DK3529262T3 (sr) |
| ES (1) | ES2883678T3 (sr) |
| HR (1) | HRP20211544T1 (sr) |
| HU (1) | HUE056016T2 (sr) |
| IL (1) | IL266111B (sr) |
| LT (1) | LT3529262T (sr) |
| MA (1) | MA46570B1 (sr) |
| MD (1) | MD3529262T2 (sr) |
| PL (1) | PL3529262T3 (sr) |
| RS (1) | RS62463B1 (sr) |
| SI (1) | SI3529262T1 (sr) |
| WO (1) | WO2018073440A1 (sr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102646708B1 (ko) * | 2016-10-21 | 2024-03-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | T 세포 반응을 촉진하는 방법 |
| JP2022520138A (ja) * | 2018-08-28 | 2022-03-29 | ブイオーアール バイオファーマ インコーポレーテッド | 遺伝子操作された造血幹細胞およびそれらの使用 |
| JP2023504733A (ja) | 2019-12-05 | 2023-02-06 | オーエスイー・イミュノセラピューティクス | 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片 |
| AU2022290831A1 (en) | 2021-06-08 | 2024-01-18 | Institut National de la Santé et de la Recherche Médicale | Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof |
| WO2023083890A1 (en) * | 2021-11-09 | 2023-05-19 | Ose Immunotherapeutics | Identification of clec-1 ligand and uses thereof |
| WO2024028347A1 (en) | 2022-08-01 | 2024-02-08 | Ose Immunotherapeutics | Heterodimeric fc-clec-1 fusion molecule and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
| JPH09500125A (ja) | 1993-07-15 | 1997-01-07 | キャンサー リサーチ キャンペーン テクノロジー リミテッド | タンパク質チロシンキナーゼインヒビターのプロドラッグ |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6498165B1 (en) | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CA2376951A1 (en) | 1999-06-30 | 2001-01-04 | Peter J. Sinclair | Src kinase inhibitor compounds |
| AU6605200A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| BR0013899A (pt) | 1999-09-10 | 2003-07-08 | Merck & Co Inc | Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral |
| AU778042B2 (en) | 1999-10-19 | 2004-11-11 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| IL148891A0 (en) | 1999-10-19 | 2002-09-12 | Merck & Co Inc | Tyrosine kinase inhibitors |
| JP5007007B2 (ja) * | 1999-11-15 | 2012-08-22 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞 |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| JP2004535437A (ja) | 2001-06-22 | 2004-11-25 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
| US6958340B2 (en) | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6927293B2 (en) | 2001-08-30 | 2005-08-09 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US8246959B1 (en) | 2003-08-01 | 2012-08-21 | University Of Washington | Dendritic cell-associated lectin-like molecules, compositions and methods of use |
| US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| CN101668777A (zh) * | 2007-02-23 | 2010-03-10 | 贝勒研究院 | 通过clec-6激活人抗原呈递细胞 |
| WO2011105424A1 (ja) * | 2010-02-23 | 2011-09-01 | 国立大学法人東京大学 | 樹状細胞免疫受容体刺激剤 |
| TWI718992B (zh) * | 2014-07-21 | 2021-02-21 | 瑞士商諾華公司 | 使用cll-1嵌合抗原受體治療癌症 |
| KR102646708B1 (ko) | 2016-10-21 | 2024-03-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | T 세포 반응을 촉진하는 방법 |
-
2017
- 2017-10-20 KR KR1020197014209A patent/KR102646708B1/ko active IP Right Grant
- 2017-10-20 MD MDE20190953T patent/MD3529262T2/ro unknown
- 2017-10-20 HU HUE17797066A patent/HUE056016T2/hu unknown
- 2017-10-20 ES ES17797066T patent/ES2883678T3/es active Active
- 2017-10-20 WO PCT/EP2017/076911 patent/WO2018073440A1/en active Application Filing
- 2017-10-20 US US16/343,757 patent/US11365257B2/en active Active
- 2017-10-20 IL IL266111A patent/IL266111B/en unknown
- 2017-10-20 AU AU2017345286A patent/AU2017345286B2/en active Active
- 2017-10-20 CA CA3039348A patent/CA3039348C/en active Active
- 2017-10-20 RS RS20211221A patent/RS62463B1/sr unknown
- 2017-10-20 MA MA46570A patent/MA46570B1/fr unknown
- 2017-10-20 DK DK17797066.2T patent/DK3529262T3/da active
- 2017-10-20 SI SI201730876T patent/SI3529262T1/sl unknown
- 2017-10-20 EP EP21178847.6A patent/EP3950709B1/en active Active
- 2017-10-20 PL PL17797066T patent/PL3529262T3/pl unknown
- 2017-10-20 CN CN201780065072.6A patent/CN110291102A/zh active Pending
- 2017-10-20 LT LTEPPCT/EP2017/076911T patent/LT3529262T/lt unknown
- 2017-10-20 EP EP17797066.2A patent/EP3529262B1/en active Active
- 2017-10-20 HR HRP20211544TT patent/HRP20211544T1/hr unknown
- 2017-10-20 JP JP2019521034A patent/JP7032396B6/ja active Active
-
2021
- 2021-09-24 CY CY20211100839T patent/CY1124584T1/el unknown
-
2022
- 2022-02-22 JP JP2022025697A patent/JP7404418B6/ja active Active
- 2022-05-10 US US17/740,849 patent/US20220281983A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274903A (en) | cell | |
| HK1246825A1 (zh) | 細胞 | |
| HK1250667A1 (zh) | 細胞 | |
| HK1252162A1 (zh) | 細胞 | |
| GB201621889D0 (en) | Cell | |
| GB201507368D0 (en) | Cell | |
| GB201503500D0 (en) | Cell | |
| GB201610515D0 (en) | Cell | |
| GB201522097D0 (en) | Cells | |
| GB201611982D0 (en) | Cell culture | |
| GB201616238D0 (en) | Modified T cells | |
| IL266111A (en) | Methods for inducing a t-cell response | |
| GB201603372D0 (en) | Cell | |
| ZA201900891B (en) | B-cell-mimetic cells | |
| GB201609604D0 (en) | Cell | |
| GB201617716D0 (en) | Cell | |
| PL3287521T3 (pl) | Hodowla komórkowa | |
| PL3149792T3 (pl) | Ogniwo litowo-siarkowe | |
| GB201604427D0 (en) | Modified cell | |
| PT3529262T (pt) | Métodos para promover resposta de células t | |
| PL3560023T3 (pl) | Elektrolit do baterii litowo-jonowych | |
| SG10202010002RA (en) | Cell culture | |
| GB201507819D0 (en) | Cell | |
| GB201507816D0 (en) | Cell | |
| GB201507814D0 (en) | Cell |